

Wilson Disease Market Size in the 7MM was ~USD 290 Million in 2022, estimated DelveInsight

Wilson Disease Market Size

DELHI, DELHI, INDIA, June 11, 2024 /EINPresswire.com/ -- DelveInsight's 'Wilson's Disease Market Insights, Epidemiology, and Market Forecast - 2034' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Wilson Disease in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.



Wilson Disease Market

Explore the intricate details of the Wilson Disease Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Wilson Disease Market Forecast. Click here to stay ahead in healthcare innovation @ [Wilson Disease Market Size](#)

Key Takeaways from the Wilson Disease Market Report

- May 2024:- Ultragenyx Pharmaceuticals Inc.- The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the effect of UX701 on copper regulation.
- Assessments as per DelveInsight's analysts showed that in 2022, in Germany there was around 916 cases of Wilson's disease was diagnosed which will increase by 2034.
- Assessments as per DelveInsight's analysts showed that there were around 1,321 cases with hepatic manifestation, 535 cases with neurologic manifestation, 348 neuro-hepatic cases and 425 cases with other manifestations of Wilson's disease in the United States in 2022. DelveInsight estimates that the prevalence of these manifestations will increase by 2034.
- In 2022, the prevalent population of Wilson's disease in the United States was found to be around 9,189 cases out of which nearly 2,630 cases were diagnosed, as per DelveInsight's estimates, the cases is expected to increase by 2034.
- Key Wilson Disease companies working in the Wilson Disease market are Orphalan,

AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, and others.

- Promising Wilson Disease Therapies such as VTX-801, UX701, and others.

Delve deep into the Wilson Disease Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Wilson Disease Market Forecast. Click here to shape the future @ [Wilson Disease Epidemiology Insights](#)

Wilson Disease Overview

Wilson's disease (WD) is a genetic disorder that prevents the body from removing extra copper, causing copper to build up in the liver, brain, eyes, and other organs. Without treatment, high copper levels can cause life-threatening organ damage. Wilson's disease also known as hepatolenticular degeneration is caused by mutations in the ATP7B gene, which is responsible for transporting copper from intracellular chaperone proteins into the secretory pathway, both for excretion into bile and for incorporation into apo-ceruloplasmin for the synthesis of functional ceruloplasmin. This defect results in progressive toxic accumulation of copper in the liver that begins in infancy when copper-containing solids are introduced into the diet.

Wilson Disease Epidemiology Insights

- Prevalent Cases
- Diagnosed Prevalent cases on Clinical Manifestation
- Diagnosed Prevalent Cases
- Diagnosed Prevalent cases of based on Symptoms

Navigate the complexities of the Wilson Disease Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Wilson Disease Market Forecast. Click here to get more insights @ [Wilson Disease Treatment Market](#)

Wilson Disease Treatment Landscape

Wilson's disease treatment includes three types of medications: first those that remove (chelate) copper from the body by urinary excretion, such as penicillamine (Cuprimine) and trientine dihydrochloride (Syprine), second, zinc salts to prevent the gut from absorbing copper from the diet, and third, tetrathiomolybdate which both prevents absorbing copper and binds up toxic copper in the blood making it nontoxic.

Wilson Disease Market Insights

There is currently no cure for Wilson's disease. The main aim of the current treatment is to establish a negative copper balance with the life-long administration of chelating agents (D-penicillamine, trientine salts) or zinc salt. D-penicillamine is available under the brand name Cuprimine and Depen while trientine under Syprine and Trientine Dihydrochloride (Cufence). Treatment helps to improve the manifestations of the disease over time, and its effectiveness depends on strict adherence to it throughout life. Restriction of copper-rich foods may be beneficial. Liver transplantation is the recommended therapy in cases of acute liver failure with encephalopathy or decompensated cirrhosis despite drug therapy.

Unlock insights into the Wilson Disease Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Wilson Disease Market Forecast. Click here @ Wilson Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/wilson-disease-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Wilson Disease Market Dynamics

The Wilson's disease market dynamics are anticipated to change in the coming years owing to the improvement in the research and development undertaking. Despite advancements in treatment, there are a number of unmet needs in treatment management that must be addressed in order to produce successful and safe Wilson's disease therapies to meet the demands of patients.

Wilson Disease Drugs Uptake

- VTX-801 by Vivet Therapeutics and Pfizer is a novel, investigational rAAV-based gene therapy vector that delivers a miniaturized ATP7B transgene encoding. This functional protein has been shown to restore copper homeostasis, reverse liver pathology, and reduce copper accumulation in the brain of a mouse model of Wilson's disease. VTX-801's rAAV serotype was selected based on its demonstrated tropism for transducing human liver cells.
- UX701 by Ultragenyx Pharmaceutical is an investigational AAV type 9 gene therapy designed to deliver a stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion. The therapy has been shown in preclinical studies to improve copper distribution and excretion from the body and reverse pathological findings of Wilson's liver disease.

Discover more about Wilson Disease Drugs in development @ Wilson Disease Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/wilson-disease-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Wilson Disease Market Report

- Coverage- 7MM
- Wilson Disease Companies- Orphan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, and others.
- Wilson Disease Therapies- VTX-801, UX701, and others.
- Wilson Disease Market Dynamics: Wilson Disease Market drivers and Wilson Disease Market Barriers
- Wilson Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Wilson Disease Unmet Needs, KOL's views, Analyst's views, Wilson Disease Market Access and Reimbursement

Gain a strategic edge in the Wilson Disease Market: explore comprehensive drug insights,

treatment updates, and epidemiological forecasts in our in-depth Wilson Disease Market Forecast. Click here to lead in advancements @ Wilson Disease Clinical Trials Assessment-
https://www.delveinsight.com/sample-request/wilson-disease-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Wilson's Disease Market Key Insights
2. Wilson's Disease Market Report Introduction
3. Wilson's Disease Market Overview at a Glance
4. Wilson's Disease Market Executive Summary
5. Disease Background and Overview
6. Wilson's Disease Treatment and Management
7. Wilson's Disease Epidemiology and Patient Population
8. Patient Journey
9. Wilson's Disease Marketed Drugs
10. Wilson's Disease Emerging Drugs
11. Seven Major Wilson's Disease Market Analysis
12. Wilson's Disease Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Yash Bhardwaj
DelveInsight
+91 9650213330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/719048133>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.